ストックスクリーナーアプリを入手
4.57
5.54%
0.24
アフターアワーズ：
4.53
-0.04
-0.88%
Rezolute Inc (RZLT) 最新ニュース
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD) - The Globe and Mail
RZLT Maintained by Guggenheim -- Price Target Raised to $11.00 - GuruFocus
Guggenheim raises Rezolute stock price target on trial outlook - Investing.com UK
Guggenheim raises Rezolute stock price target on trial outlook By Investing.com - Investing.com Canada
Exploring 3 High Growth Tech Stocks in US Market - simplywall.st
RZLT stock on the move: What sparks the 38% jump in the past week? - MSN
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL) - The Globe and Mail
Positive Signs As Multiple Insiders Buy Rezolute Stock - Yahoo Finance
RZLT Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Cautious OutlookDiluted EPS Report - newsline.com
Craig-Hallum Keeps Their Hold Rating on Rezolute (RZLT) - The Globe and Mail
REZOLUTE INC (RZLT) Stock Chart - ChartMill
RZLT: Strong interim efficacy in tumor HI and key regulatory milestones expected later this year - TradingView
RZLT: Strong interim efficacy in tumor HI and regulatory clarity for congenital HI expected this year - TradingView
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? - The Globe and Mail
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society - The Manila Times
Rezolute, Inc. Announces Four Presentations at the 2026 Annual Meeting of the Endocrine Society on Ersodetug for Congenital Hyperinsulinism - Quiver Quantitative
Rezolute (RZLT) Receives a Buy from Guggenheim - The Globe and Mail
Phase 3 congenital hyperinsulinism study results to be shared at ENDO 2026 - Stock Titan
RZLT Maintained by Maxim Group -- Price Target Raised to $14.00 - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY) - The Globe and Mail
Rezolute (RZLT) Gains on Upgrade Following Positive Trial Data - GuruFocus
Rezolute upgraded at Citizens after late-stage trial data for lead asset - Seeking Alpha
RZLT Maintained by Wedbush -- Price Target Raised to $6.00 - GuruFocus
RZLT Upgraded by Citizens -- Price Target Announced at $11.00 - GuruFocus
Cantor Fitzgerald reiterates Neutral on Rezolute stock on trial data By Investing.com - Investing.com Australia
A Quick Look at Today's Ratings for Rezolute(RZLT.US), With a Forecast Between $5 to $14 - Moomoo
Rezolute’s stock up on interim Phase III tumour HI data - Yahoo Finance
Cantor Fitzgerald reiterates Neutral on Rezolute stock on trial data - Investing.com
Wedbush Adjusts Price Target on Rezolute to $6 From $5, Maintains Outperform Rating - marketscreener.com
Rezolute Price Target Raised to $6.00/Share From $5.00 by BTIG - Moomoo
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Raises Target Price to $14 - Moomoo
Rezolute (RZLT) Shares Rise on Positive Trial Update for Ersodet - GuruFocus
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study - Benzinga
RZLT Reiterates by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus
Rezolute rises after late-stage trial update (RZLT:NASDAQ) - Seeking Alpha
Rezolute Announces Positive Interim Phase 3 upLIFT Results for Ersodetug in Tumor Hyperinsulinism, Six of Eight Responders Achieved IV Glucose Discontinuation 1 - Minichart
Rezolute (RZLT) Shares Phase 3 Study Progress of Ersodetug in Tu - GuruFocus
Rezolute reports interim data from tumor hyperinsulinism trial By Investing.com - Investing.com South Africa
Rezolute Reports Positive Phase 3 Data for Ersodetug - TipRanks
Rezolute reports interim data from tumor hyperinsulinism trial - Investing.com
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism - The Manila Times
Rezolute interim Phase 3 upLIFT data: 6 of 8 meet primary responder criterion; study 50% enrolled - TradingView
Rezolute (NASDAQ: RZLT) reports positive Phase 3 upLIFT tumor HI data - Stock Titan
Rezolute Shares Rise After Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial - marketscreener.com
Rezolute (RZLT) Q1 2026 Earnings: EPS Surpasses Estimates Amid Continued R&D ProgressEstimate Accuracy - The Legal Advocate
RZLT Q1 2026 Earnings: EPS Beat Expectations Despite Negative Stock ReactionEarnings Weakness Phase - newsline.com
Rezolute (RZLT) Edges Higher: Key Levels to Watch After 1.08% GainOutside Reversal - newsline.com
RZLT Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Clinical Pipeline AdvancesEarnings Momentum Score - newsline.com
Rezolute Inc. (RZLT) Slides Amid Sector Pressure: Key Levels to WatchBPI Reversal - newsline.com
RZLT Stock Price, Quote & Chart | REZOLUTE INC (NASDAQ:RZLT) - ChartMill
Opaleye Management Inc. Increases Stake in Rezolute Inc. - GuruFocus
Balyasny holds 5,048,421 shares of Rezolute (NASDAQ: RZLT), ~5.28% stake - Stock Titan
RZLT Maintains by Maxim Group -- Price Target Raised to $10.00 - GuruFocus
FDA review puts Rezolute's genetic disorder drug path in question - MSN
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Wedbush Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $10 - Moomoo
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):